BDBM221050 N-acetyl ciprofloxacin
1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid US11590142, Compound Ciprofloxacin Cipro 1-cyclopropyl-6-fluoro-4-oxo-7-piperazin-1-yl-1,4-dihydroquinoline-3-carboxylic acid Bay 09867 US9138393, Ciprofloxacin HCl Ciprinol Ciprofloxacin US9144538, Ciprofloxacin HCl BDBM21690 CHEMBL8
- Ibrahim, NM; Fahim, SH; Hassan, M; Farag, AE; Georgey, HH Design and synthesis of ciprofloxacin-sulfonamide hybrids to manipulate ciprofloxacin pharmacological qualities: Potency and side effects. Eur J Med Chem 228: (2022)
- Plech, T; Kapron, B; Paneth, A; Kosikowska, U; Malm, A; Strzelczyk, A; Staczek, P; Swiatek, L; Rajtar, B; Polz-Dacewicz, M Search for factors affecting antibacterial activity and toxicity of 1,2,4-triazole-ciprofloxacin hybrids. Eur J Med Chem 97: 94-103 (2015)
- Synthesis of novel ciprofloxacin-avibactam conjugates for the development of second-generation non-?-lactam-?-lactamase inhibitors.
- Azéma, J; Guidetti, B; Dewelle, J; Le Calve, B; Mijatovic, T; Korolyov, A; Vaysse, J; Malet-Martino, M; Martino, R; Kiss, R 7-((4-Substituted)piperazin-1-yl) derivatives of ciprofloxacin: synthesis and in vitro biological evaluation as potential antitumor agents. Bioorg Med Chem 17: 5396-407 (2009)
- Samir, M; Ramadan, M; Abdelrahman, MH; Elbastawesy, MAI; Halby, HM; Abdel-Aziz, M; Abuo-Rahma, GEA New potent ciprofloxacin-uracil conjugates as DNA gyrase and topoisomerase IV inhibitors against methicillin-resistant Staphylococcus aureus. Bioorg Med Chem 73: (2022)
- Kassab, AE; Gedawy, EM Novel ciprofloxacin hybrids using biology oriented drug synthesis (BIODS) approach: Anticancer activity, effects on cell cycle profile, caspase-3 mediated apoptosis, topoisomerase II inhibition, and antibacterial activity. Eur J Med Chem 150: 403-418 (2018)